Anti-LPS Antibody Treatment for Pediatric NAFLD
Anti-LPS Antibody in Pediatric Nonalcoholic Fatty Liver Disease
Sponsor: Advanced MR Analytics AB
Listed as NCT03042767, this PHASE2 trial focuses on Nonalcoholic Fatty Liver Disease (NAFLD) and remains completed. Sponsored by Advanced MR Analytics AB, it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Aug 2019 — Jun 2020 [monthly]
Recruiting PHASE2
-
Oct 2018 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Advanced MR Analytics AB
- Immuron Ltd.
- Miriam Vos, MD
For direct contact, visit the study record on ClinicalTrials.gov .